Oncology
Harnessing Macrophage Biology to Overcome Tumor Immune Evasion
Roy Maute, Ph.D.
Pheast Therapeutics
PAO-07-26-CL-03Jul 23, 2026
Stem Cells
Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-26-PA-11Jul 22, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19Jul 20, 2026
Rare Cancer CGT
Developing Cell and Gene Therapies for Rare Oncology Applications
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-10Jul 16, 2026
Drug Delivery
Intracellular Delivery: Reaching Targets Beyond the Cell Surface
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-07Jul 14, 2026
Tumor-Agnostic
Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-05Jul 8, 2026
Next-Gen Delivery
Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms
Pharma's Almanac
PAO-07-26-PA-06Jul 6, 2026
Protein Conformation
Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-17Jul 6, 2026
Organoids
Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research
Seahee Kim, Ph.D.
Samsung Biologics
PAO-06-26-CL-04Jul 1, 2026
LAIs
The Long View: How Extended-Duration Therapies Are Reshaping Patient Care
Pharma's Almanac
PAO-07-26-PA-01Jul 1, 2026
Genome Engineering
Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-16Jun 29, 2026
Microbiome Editing
Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-15Jun 22, 2026
CNS Clinical
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969
Insilico Medicine
PR-06-26-01Jun 17, 2026
Expedited Pathways
Accelerated Pathways: Are They Delivering on Their Promise?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-10Jun 17, 2026
Protein Misfolding
Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-08Jun 15, 2026
Alzheimer Therapies
Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-05Jun 10, 2026
Protein Engineering
Exponential Advances in Protein Engineering
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-26-PA-04Jun 8, 2026
BsAbs
Why Bispecific Antibody Architecture Is a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-01Jun 2, 2026
Dark Proteins
Dark Proteins Step Into the Light
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-05-26-PA-26May 26, 2026
Oligo Analytics
Impurities, Sequence Fidelity, and Structural Variants in Nucleic Acid Therapeutics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-23May 26, 2026